AbbVie (ABBV) Declares $1.18 Quarterly Dividend; 4.9% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
UPDATE: Abbvie (ABBV) PT Raised to $109 at UBS; Pipeline Emerging and Expanding
June 17, 2020 5:38 AM EDT(Updated - June 17, 2020 7:53 AM EDT)
(updated to add analyst comments)
UBS analyst Navin Jacob raised the price target on Abbvie (NYSE: ABBV) to $109.00 (from $96.00) while maintaining a Buy rating, noting the pipeline is emerging and expanding.
The analyst... More
AbbVie (ABBV) Announces FDA Approves JUVEDERM VOLUMA XC for Enhancement of Chin Region
June 15, 2020 8:15 AM EDTToday Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the FDA approval of JUVÉDERM® VOLUMA XC for the augmentation of the chin region to improve the chin profile in adults over the age of 21.1 As the category leader, the JUVÉDERM® Collection of Fillers has the broadest portfolio of specifically tailored treatment options, and this latest approval marks their fifth approved indication in the U.S.1-5
"When assessing facial anatomy, the chin is a critical component to facial balance, yet it is often overlooked. Due to its... More
